西达本胺维持治疗预防外周T细胞淋巴瘤自体造血干细胞移植术后复发的临床观察

Clinical observation of sidabendamine maintenance therapy to prevent recurrence of peripheral T cell lymphoma after autologous hematopoietic stem cell transplantation

目的讨论西达本胺维持治疗预防外周T细胞淋巴瘤自体造血干细胞移植术后复发的临床观察。方法入选48例外周T细胞淋巴瘤自体造血干细胞移植术患者主要于2017年1月-2020年6月接受诊疗,以自体造血干细胞移植术后是否接受西达本胺维持治疗分为对照组24例与研究组24例。对照组未接受持续性维持治疗,研究组接受西达本胺治疗。观察指标:术后2年病情客观缓解率、术后2内复发率、研究组西达本胺不良反应情况。结果研究组术后2年病情客观缓解率为70.83%,明显高于对照组术后2年病情客观缓解率的41.67%,差异有统计学意义(P<0.05)。研究组术后2年复发率为25%,明显低于对照组术后2年复发率的54.17%,差异有统计学意义(P<0.05)。24例研究组患者接受西达本胺治疗1个月内有8例发生血液学不良反应,治疗期间还有6例胃肠道反应、6例乏力、1例心脏毒副反应、1例肝肾轻度损害。结论西达本胺维持治疗预防外周T细胞淋巴瘤自体造血干细胞移植术后复发有良好效果,可显著提高患者术后病情客观缓解率,不良反应轻。

Objective To discuss the clinical observation of sidabendamine maintenance therapy in the prevention of recurrence of peripheral T-cell lymphoma after autologous hematopoietic stem cell transplantation.Methods A total of 48 patients with peripheral T-cell lymphoma undergoing autologous hematopoietic stem cell transplantation were enrolled from January 2017 to June 2020.They were divided into control group(n=24)and study group(n=24)according to whether they received sidabenamine maintenance therapy after autologous hematopoietic stem cell transplantation.The control group did not receive continuous maintenance treatment,and the study group received sidabenamine treatment.Observation indexes:objective remission rate 2 years after operation,recurrence rate within 2 years after operation,and adverse reactions of sidabenamine in the study group.Results The objective remission rate in the study group was 70.83%,which was significantly higher than 41.67%in the control group,and the difference was statistically significant(P<0.05).The recurrence rate within 2 days after operation in the study group was 25%,which was significantly lower than 54.17%in the control group,and the difference was statistically significant(P<0.05).Among the 24 patients in the study group,hematological adverse reactions occurred in 8 cases,gastrointestinal reactions in 6 cases,fatigue in 6 cases,cardiac side effects in 1 case,and mild liver and kidney damage in 1 case within 1 month after receiving sidabenamine treatment.Conclusion Sidabenamine maintenance therapy has a good effect on preventing recurrence of peripheral T-cell lymphoma after autologous hematopoietic stem cell transplantation.It can significantly improve the objective remission rate of patients after surgery,and has mild adverse reactions.